Featured Research Search Results

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT05384535

Prevention
Screening for people at high risk for prostate cancer

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Hormone Replacement Therapy After Risk-Reducing Surgery in Individuals at Increased Risk for Breast Cancer: The Patient Perspective

Surveys, Registries, Interviews
Survey for individuals with a BRCA1, BRCA2, PALB2, RAD51C, RAD51D mutation

Research Study on the Genetics of Breast Cancer

Clinicaltrials.gov identifier:
NCT06773897

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Screening Study for Pancreatic Cancer in People with Inherited Mutations

Clinicaltrials.gov identifier:
NCT05058846

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Pancreatic Cancer Screening Study (CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Registry for People at Increased Risk for Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06151223

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1

Clinicaltrials.gov identifier:
NCT06120491

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Treating Metastatic BRCA1, BRCA2 or PALB2 Pancreatic Cancer Using a New Combination of Chemotherapy Drugs

Clinicaltrials.gov identifier:
NCT06115499

Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

Cancer Risk Perception and Management of Individuals With a BRCA1 or BRCA2 Mutation Who Were Assigned Male at Birth (AMAB)

Surveys, Registries, Interviews
Research study enrolling individuals assigned male at birth (AMAB) who have a BRCA1 and/or BRCA2 mutation

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Clinicaltrials.gov identifier:
NCT04472338

Prevention
Screening study for people with a mutation linked to prostate cancer risk